Isomorphic Labs, the AI-first drug design company spun out of Google DeepMind in 2021, announced a $2.1 billion Series B funding round on May 12, 2026 — one of the largest private investments ever made in AI-driven drug discovery. The round brings the company's total capital raised to approximately $2.6 billion as it prepares to advance its first AI-designed drug candidates into clinical trials by the end of 2026.
Key Highlights
- Isomorphic Labs raised $2.1 billion in a Series B round led by Thrive Capital
- Investors include Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund
- The company's drug design engine (IsoDDE) is informally called "AlphaFold 4" by scientists
- Active partnerships with Novartis, Eli Lilly, and Johnson & Johnson are already in place
- First clinical trials expected by the end of 2026
The Technology Behind the Funding
At the heart of Isomorphic Labs' work is IsoDDE — the Isomorphic Drug Design Engine. Scientists have informally nicknamed it "AlphaFold 4," reflecting its deep roots in the protein-structure prediction technology that revolutionized structural biology. Unlike traditional drug discovery, which relies on years of laboratory experiments and costly trial-and-error, IsoDDE uses a unified AI system to model molecular interactions, predict biological activity, and design entirely new drug candidates across multiple therapeutic areas.
Max Jaderberg, President of Isomorphic Labs, described the engine as providing "a repeatable way to design new medicines for a wide range of diseases" — a vision that has attracted some of the world's largest pharmaceutical companies.
Who Invested and Why
The Series B was led by Thrive Capital — the same firm that led Isomorphic's earlier fundraise — signaling high confidence in the company's trajectory. New investors MGX (Abu Dhabi's AI and advanced technology investment arm), Temasek (Singapore's state investment fund), and the UK Sovereign AI Fund joined alongside returning backers Alphabet, GV, and CapitalG.
Joshua Kushner, CEO of Thrive Capital, praised the company for building "a unified AI drug design engine to define a new age of drug discovery."
The presence of sovereign wealth funds from the UK, Abu Dhabi, and Singapore underscores the geopolitical dimension of AI in healthcare: nations are beginning to treat AI-powered drug discovery as a strategic asset, not just a business opportunity.
From DeepMind Spinout to Clinical Stage Company
Founded in 2021 as a direct spinout from Google DeepMind, Isomorphic Labs was conceived by Sir Demis Hassabis — the Nobel Prize-winning scientist who co-created AlphaFold — to apply the breakthrough in protein-structure prediction to the full drug discovery pipeline.
"This capital injection allows us to build out our drug design engine at scale," said Hassabis in the funding announcement, reinforcing the company's mission to "leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally."
The company is headquartered in London, with additional offices in Cambridge, Massachusetts, and Lausanne, Switzerland. It has active drug-design collaborations with three of the world's largest pharmaceutical companies — Novartis, Eli Lilly, and Johnson & Johnson — all of which are using IsoDDE to discover small molecule drug candidates for undisclosed disease targets.
Clinical Trials on the Horizon
The $2.1 billion raise comes at a pivotal moment. Demis Hassabis had initially targeted clinical trials by end of 2025, but at the World Economic Forum in January 2026, he pushed the timeline to end of 2026. With this funding, Isomorphic now has the capital and resources to meet that revised target.
The funding will be used to:
- Accelerate development of the IsoDDE platform and its next-generation models
- Expand Isomorphic's in-house pipeline of drug candidates toward the clinic
- Grow the team globally across AI research, drug design, engineering, and clinical roles
Impact on the AI Biotech Landscape
Isomorphic's Series B is one of the single largest private funding rounds in the history of AI biotechnology. It reflects a broader shift in how the pharmaceutical industry views AI: no longer as a peripheral tool, but as the central engine of drug design.
For the wider AI industry, the round also signals that AI's value is extending far beyond software productivity tools into life sciences — an area where AI could eventually save millions of lives by dramatically cutting the time and cost required to bring new medicines to patients.
What's Next
With $2.6 billion in total capital and partnerships with three pharma giants already active, Isomorphic Labs is on track to become the first company to put a fully AI-designed drug into human clinical trials. If successful, this would mark a watershed moment not just for AI in healthcare, but for the broader field of applied AI.
The next major milestone — a Phase 1 clinical trial announcement — is expected before the end of 2026.